Development of an mRNA-lipid nanoparticle vaccine against Lyme disease

• DOI: 10.1016/j.ymthe.2023.07.022
• Publication Date: 2023-08-02T07:20:10Z
• Authors: Matthew Pine; Gunjan Arora; Thomas M. Hart; Emily Bettini; Brian T. Gaudette; Hiromi Muramatsu; István Tombácz; Taku Kambayashi; Ying K. Tam; Dustin Brisson; David Allman; Michela Locci; Drew Weissman; Erol Fikrig; Norbert Pardi
• Keywords: LYME

Lyme disease is the most common vector-borne infectious in United States, part because a vaccine against it not currently available for humans. We propose utilizing lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform to generate like successful clinical vaccines SARS-CoV-2. Of antigens expressed by Borrelia burgdorferi, causative agent of disease, outer surface protein A (OspA) promising candidate development. have designed and synthesized an OspA-encoding mRNA-LNP compared its immunogenicity protective efficacy alum-adjuvanted OspA subunit vaccine. induced superior humoral cell-mediated immune responses mice after single immunization. These potent resulted protection bacterial infection. Our study demonstrates that highly efficient can be developed targets.